2021
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas
Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T, Nassar A, Han X, Sanmamed MF, Youngblood M, Peyre M, Kalamarides M, Rimm DL, Gunel M, Chen L. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology 2021, 23: 1922-1935. PMID: 33914067, PMCID: PMC8563319, DOI: 10.1093/neuonc/noab075.Peer-Reviewed Original ResearchConceptsColony-stimulating factor-1Myeloid cellsMalignant meningiomasTumor microenvironmentCSF1/CSF1RRNA-seqRNA sequencingHuman meningiomasImmune subsetsGene expressionT cellsTreatment strategiesNormalization cancer immunotherapyImportant regulatorCell typesNovel immunocompetent murine modelDeath ligand 1 (PD-L1) expressionCell death receptor-1Immunosuppressive myeloid cellsDeath receptor-1Ligand 1 expressionFactor 1Immune cell typesImmunocompetent murine modelEffective treatment strategiesA Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
Sanmamed MF, Nie X, Desai SS, Villaroel-Espindola F, Badri T, Zhao D, Kim AW, Ji L, Zhang T, Quinlan E, Cheng X, Han X, Vesely MD, Nassar AF, Sun J, Zhang Y, Kim TK, Wang J, Melero I, Herbst RS, Schalper KA, Chen L. A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. Cancer Discovery 2021, 11: 1700-1715. PMID: 33658301, PMCID: PMC9421941, DOI: 10.1158/2159-8290.cd-20-0962.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTumor-infiltrating lymphocytesExhausted T cellsTIL subsetsTumor microenvironmentCancer immunotherapyT cellsAdvanced non-small cell lung cancerPatient-derived tumor xenograft modelAnti-PD therapyT cell subsetsCell lung cancerPotential tissue biomarkersBaseline tumor tissueLung cancer tissuesSingle-cell mass cytometryTumor xenograft modelApoptotic CD8Dysfunctional CD8Immunotherapy resistancePD-1Activation markersAdjacent nontumoral tissuesPathway-dependent mannerLung cancer
2019
PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
Han X, Vesely MD, Yang W, Sanmamed MF, Badri T, Alawa J, López-Giráldez F, Gaule P, Lee SW, Zhang JP, Nie X, Nassar A, Boto A, Flies DB, Zheng L, Kim TK, Moeckel GW, McNiff JM, Chen L. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. Science Translational Medicine 2019, 11 PMID: 31826980, DOI: 10.1126/scitranslmed.aax1159.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsArthritisAutoantibodiesAutoimmunityDendritic CellsHumansInflammationInterferon Type ILupus Erythematosus, CutaneousLupus Erythematosus, SystemicMembrane ProteinsMice, Inbred BALB CMice, Inbred MRL lprMyeloid CellsNeutrophilsReceptors, Antigen, T-CellSignal TransductionTerpenesUp-RegulationConceptsPlasmacytoid dendritic cellsDiscoid lupus erythematosusSystemic lupus erythematosusCutaneous lupus lesionsPD-1HLupus erythematosusLupus lesionsAutoimmune diseasesKO miceT cellsMyeloid cellsHuman systemic lupus erythematosusBALB/c backgroundCutaneous lupus erythematosusInappropriate immune responseProgression of lupusSystemic autoimmune diseaseImmune cell expansionSuppression of autoimmunityAgonistic monoclonal antibodyDeath-1 homologCutaneous lupusProinflammatory neutrophilsDendritic cellsDLE lesions
2018
Development and Validation of LC–MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human Plasma
Nassar AF, Wisnewski AV, Wu T, Lam TT, King I. Development and Validation of LC–MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human Plasma. Journal Of Chromatographic Science 2018, 57: 195-203. PMID: 30395213, DOI: 10.1093/chromsci/bmy100.Peer-Reviewed Original Research
2017
Polymerization of hexamethylene diisocyanate in solution and a 260.23 m/z [M+H]+ ion in exposed human cells
Wisnewski AV, Liu J, Redlich CA, Nassar AF. Polymerization of hexamethylene diisocyanate in solution and a 260.23 m/z [M+H]+ ion in exposed human cells. Analytical Biochemistry 2017, 543: 21-29. PMID: 29175138, PMCID: PMC5826792, DOI: 10.1016/j.ab.2017.11.017.Peer-Reviewed Original ResearchConceptsHexamethylene diisocyanateCollision-induced dissociation (CID) fragmentation patternsNucleophilic additionImportant industrial chemicalPrimary aminesFragmentation patternsO groupLC-MS/MSLC-MS/MS analysisLC-MSReaction productsIonsMS analysisFormula CIndustrial chemicalsDiisocyanatePolymerizationPolymersReaction targetWaterSolutionAminesDefinitive characterizationMoleculesDimersAutomation of sample preparation for mass cytometry barcoding in support of clinical research: protocol optimization
Nassar AF, Wisnewski AV, Raddassi K. Automation of sample preparation for mass cytometry barcoding in support of clinical research: protocol optimization. Analytical And Bioanalytical Chemistry 2017, 409: 2363-2372. PMID: 28124752, PMCID: PMC5863240, DOI: 10.1007/s00216-017-0182-4.Peer-Reviewed Original Research
2016
UPLC–MS for metabolomics: a giant step forward in support of pharmaceutical research
Nassar AF, Wu T, Nassar SF, Wisnewski AV. UPLC–MS for metabolomics: a giant step forward in support of pharmaceutical research. Drug Discovery Today 2016, 22: 463-470. PMID: 27919805, PMCID: PMC5721520, DOI: 10.1016/j.drudis.2016.11.020.Peer-Reviewed Original ResearchPopulation pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients
Nassar AF, Wisnewski AV, King I. Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients. Xenobiotica 2016, 47: 394-407. PMID: 27440490, DOI: 10.1080/00498254.2016.1201703.Peer-Reviewed Original ResearchConceptsPopulation pharmacokinetic analysisInter-patient variabilityPharmacokinetic analysisSignificant single-agent activitySingle-agent activityPopulation PK analysisVolume of distributionHigh inter-patient variabilityInter-occasion variabilityAlkylating agentCancer patientsTotal clearanceTotal body waterClinical trialsHematologic malignanciesPK analysisDosing cyclesOrgan functionSolid tumorsAntineoplastic alkylating agentCentral compartmentNONMEM analysisRapid clearancePatientsClearanceProgress in automation of mass cytometry barcoding for drug development
Nassar AF, Wisnewski AV, Raddassi K. Progress in automation of mass cytometry barcoding for drug development. Bioanalysis 2016, 8: 1429-1435. PMID: 27323800, DOI: 10.4155/bio-2016-0135.Peer-Reviewed Original ResearchBiotransformation and Rearrangement of Laromustine
Nassar AE, Wisnewski AV, King I. Biotransformation and Rearrangement of Laromustine. Drug Metabolism And Disposition 2016, 44: 1349-1363. PMID: 27278961, DOI: 10.1124/dmd.116.069823.Peer-Reviewed Original ResearchConceptsNuclear magnetic resonance spectroscopyCollision-induced dissociationFourier transform ion cyclotron resonance mass spectrometerIon cyclotron resonance mass spectrometerAccurate mass measurementsMass spectrometry studiesHydrogen-deuterium exchangeMagnetic resonance spectroscopyMass spectral rearrangementsExact massSpectrometry studiesEnzyme catalysisReactive intermediatesMass spectrometerDecomposition productsResonance spectroscopyConjugation reactionsElemental compositionPossibility of rearrangementMass measurementsSpectral rearrangementsDissociationRadioactive componentsLoss of nitrogenMetabolite productsMass cytometry moving forward in support of clinical research: advantages and considerations
Nassar AF, Wisnewski AV, Raddassi K. Mass cytometry moving forward in support of clinical research: advantages and considerations. Bioanalysis 2016, 8: 255-257. PMID: 26847541, DOI: 10.4155/bio.15.257.Peer-Reviewed Original ResearchRapid label‐free profiling of oral cancer biomarker proteins using nano‐UPLC‐Q‐TOF ion mobility mass spectrometry
Nassar AF, Williams BJ, Yaworksy DC, Patel V, Rusling JF. Rapid label‐free profiling of oral cancer biomarker proteins using nano‐UPLC‐Q‐TOF ion mobility mass spectrometry. Proteomics Clinical Applications 2016, 10: 280-289. PMID: 26684082, DOI: 10.1002/prca.201500025.Peer-Reviewed Original ResearchConceptsIon mobility mass spectrometryCancer biomarker proteinsMass spectrometryNano-UPLCMobility mass spectrometryInterleukin-8Biomarker proteinsClinical cancer diagnosticsIon mobilityComplex samplesLabel-free profilingVascular endothelial growth factorOral cancer cellsOral cancer samplesCancer cell mediumEndothelial growth factorLabel proteinsIsotope labelingStable isotope labelingRelative quantitationSpectrometryClinical relevanceCancer cell culturesProteolytic digestionCancer development
2015
In vitro cleavage of diisocyanate-glutathione conjugates by human gamma-glutamyl transpeptidase-1
Wisnewski AV, Liu J, Nassar AF. In vitro cleavage of diisocyanate-glutathione conjugates by human gamma-glutamyl transpeptidase-1. Xenobiotica 2015, 46: 726-732. PMID: 26678254, PMCID: PMC4848134, DOI: 10.3109/00498254.2015.1118576.Peer-Reviewed Original ResearchImpact of recent innovations in the use of mass cytometry in support of drug development
Nassar AF, Ogura H, Wisnewski AV. Impact of recent innovations in the use of mass cytometry in support of drug development. Drug Discovery Today 2015, 20: 1169-1175. PMID: 26092491, PMCID: PMC4668584, DOI: 10.1016/j.drudis.2015.06.001.Peer-Reviewed Original ResearchConceptsSingle-cell technologiesSingle-cell levelDrug developmentSingle cellsDiseased statesCell levelMechanism of actionMass cytometryCellsDrug profilingIndividual biological cellsCyTOFImportant roleSignal overlapCytometryIndividual samplesBiological cellsProfilingSignificant advancesCell technologyMetabolic disposition of the anti-cancer agent [14C]laromustine in male rats
Nassar AF, Wisnewski A, King I. Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats. Xenobiotica 2015, 45: 711-721. PMID: 25798740, PMCID: PMC4681490, DOI: 10.3109/00498254.2015.1016475.Peer-Reviewed Original ResearchConceptsQuantitative whole-body autoradiographyBolus doseDrug-derived radioactivityPeak plasma concentrationWhole-body autoradiographyGroup 1 animalsUrinary bladder contentsLong-Evans ratsExcretion of drugsSmall intestine contentsRecovery of radioactivityNovel sulfonylhydrazineAnti-cancer agentsSpinal cordMale ratsPlasma concentrationsIntravenous administrationRenal cortexBladder contentsTotal bodyMetabolic dispositionOrgan exposureSmall intestineRatsMedical guidelines